Insulet Publishes 2022 Sustainability Report Focused on Innovating for the Future and Preserving the Environment
02 Maio 2023 - 7:00AM
Business Wire
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the
global leader in tubeless insulin pump technology with its Omnipod®
brand of products, today released its 2022 Sustainability Report
highlighting accomplishments in environmental, social, and
governance (ESG) across its global markets. The report details the
Company’s efforts to optimize value while revolutionizing health
outcomes and driving a sustainable future.
“As we continue to advance our mission to improve the lives of
people with diabetes, we have made significant progress in our
Company’s sustainability practices,” said Jim Hollingshead,
President and Chief Executive Officer. “By harnessing opportunities
for positive environmental, social, and governance impacts, we
continue to optimize value for our customers, communities,
investors, and employees. This is a critical aspect of our growth
strategy and I’m delighted to share our efforts in our 2022
Sustainability Report.”
Insulet’s report describes key accomplishments made over the
last 12 months, including the FDA clearance and full market release
of its flagship innovation, the Omnipod® 5 Automated Insulin
Delivery System, which automatically adjusts insulin delivery based
on readings from an integrated continuous glucose monitor. As the
Company has grown, it has implemented several meaningful projects
designed to execute on its sustainability strategy to deliver
growth with purpose.
Highlights from this year’s report include:
- Circular Economy: Insulet advanced its efforts to reduce
waste, notably through its existing product takeback programs in
the European Union, United Kingdom, and Canada, and through a pilot
program in Massachusetts. More than 150 metric tons*, or roughly
six million Pods, were responsibly disposed of through these
programs, an 11% increase over 2021.
- Diversity, Equity, and Inclusion: Insulet achieved 67%
gender, racial, or ethnic diversity on its Board of Directors, with
women representing 56% of the Board. Animal Crossings: New
Horizons™, a unique marketing campaign promoting diversity and
inclusion for people with diabetes, earned Insulet a Public
Relations Campaign Award from Fierce Pharma, a highly respected
medical technology publication. Insulet also reports on the
diversity, equity, and inclusion progress it made company-wide with
employees.
- Resilient Operations: With a continued strain on supply
chains around the world in 2022, Insulet maintained 100%
fulfillment of customer orders, as it has in recent years. At our
Acton, Massachusetts facility, we continued to implement the second
phase of our solar strategy and explore additional opportunities to
invest in clean energy. In 2022, we diverted 45% of the waste from
our offices, laboratories, distribution center, and manufacturing
facilities from landfill and incineration.
- Climate: Insulet’s 2022 Sustainability Report includes
its inaugural Task Force on Climate related Financial Disclosures
(TCFD) Index, which describes the Company’s climate-related efforts
in four thematic areas: governance, strategy, risk management, and
metrics and targets.
“As we continue to embed sustainability into our business
processes and decisions, we are seeing how this shift in mindset
will accelerate our progress to a sustainable future,” said Lisa
Brady, Vice President of Global Sustainability and Chief
Sustainability Officer. “Fueled by Insulet’s innovative spirit, our
teams are committed and inspired to make further advancements with
our environmental, social, and governance performance.”
Insulet’s newest report continues to apply the Sustainability
Reporting Standards issued by the Global Reporting Initiative
(GRI), the most prevalent international standards used to report an
organization’s sustainability impact and performance. In addition,
the 2022 Sustainability Report also aligns with the Sustainability
Accounting Standards Board (SASB). SASB is the leading standard
used by investors and public companies to ensure standardization in
reporting on ESG issues and specifically how they impact financial
performance.
The report can be found at investor.insulet.com under
Environmental, Social & Governance.
* These metrics reflect data for the European Union, U.K., and
Canada
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in
Massachusetts, is an innovative medical device company dedicated to
simplifying life for people with diabetes and other conditions
through its Omnipod product platform. The Omnipod Insulin
Management System provides a unique alternative to traditional
insulin delivery methods. With its simple, wearable design, the
tubeless disposable Pod provides up to three days of non-stop
insulin delivery, without the need to see or handle a needle.
Insulet’s flagship innovation, the Omnipod 5 Automated Insulin
Delivery System, integrates with a continuous glucose monitor to
manage blood sugar with no multiple daily injections, zero
fingersticks, and can be controlled by a compatible smartphone or
Omnipod 5 Controller. Insulet also leverages the unique design of
its Pod by tailoring its Omnipod technology platform for the
delivery of non-insulin subcutaneous drugs across other therapeutic
areas. For more information, please visit: insulet.com and
omnipod.com.
©2023 Insulet Corporation. Omnipod and Omnipod 5 are registered
trademarks of Insulet Corporation in the United States of America
and other various jurisdictions. All rights reserved. All other
trademarks are the property of their respective owners. The use of
third-party trademarks does not constitute an endorsement or imply
a relationship or other affiliation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230502005164/en/
Investor Relations: Deborah R. Gordon Vice President,
Investor Relations (978) 600-7717 dgordon@insulet.com
Media: Angela Geryak Wiczek Senior Director, Corporate
Communications (978) 932-0611 awiczek@insulet.com
Insulet (NASDAQ:PODD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Insulet (NASDAQ:PODD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024